Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2012

01.05.2012 | Preclinical Study

Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues

verfasst von: Amy C. Degnim, Daniel W. Visscher, Tanya L. Hoskin, Marlene H. Frost, Robert A. Vierkant, Celine M. Vachon, V. Shane Pankratz, Derek C. Radisky, Lynn C. Hartmann

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Investigations of breast carcinogenesis often rely upon comparisons between cancer tissue and nonmalignant breast tissue. It is unclear how well common reference sources of nonmalignant breast tissues reflect normal breast tissue. Breast tissue samples were evaluated from three sources: (1) normal donor tissues in the Susan G. Komen for the Cure® Tissue Bank at Indiana University Simon Cancer Center (KTB), (2) women who underwent reduction mammaplasty (RM) at Mayo Clinic Rochester, and (3) the Mayo Clinic Benign Breast Disease Cohort Study (BBD). Samples were examined histologically and assessed for proliferative disease and degree of lobular involution. Univariate comparisons were performed among the study groups, and multivariate analyses were performed with logistic regression to assess the association between study group and the presence of epithelial proliferative disease and complete lobular involution. Histologic data were collected for 455 KTB samples, 259 RM samples, and 319 BBD samples. Histologic findings and the frequency of epithelial proliferation were significantly different among the groups. Histologic abnormalities were seen in a minority of the KTB samples (35%), whereas an abnormality was present in 88% of RM tissues and 97.5% of BBD samples. The presence of proliferative disease (with or without atypical hyperplasia) was present in 3.3% of normal donors (3.3%), 17% of RM samples, and 34.9% of BBD samples (P < 0.0001 for each comparison). Multivariate analyses confirmed that these differences remained significant and also showed higher likelihood of complete lobular involution in the normal donor samples compared to RM and BBD tissues. Compared to benign breast disease tissues and reduction mammaplasty tissues, breast tissue samples from normal donors have significantly fewer histologic abnormalities and a higher frequency of more complete lobular involution. Breast tissue samples from normal donors represent a unique tissue resource with histologic features consistent with lower breast cancer risk.
Literatur
1.
Zurück zum Zitat Jin L, Fuchs A, Schnitt SJ et al (1997) Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 79:749–760PubMedCrossRef Jin L, Fuchs A, Schnitt SJ et al (1997) Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 79:749–760PubMedCrossRef
2.
Zurück zum Zitat Bernardes JR Jr, Nonogaki S, Seixas MT et al (1999) Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int J Gynaecol Obstet 67:33–38PubMedCrossRef Bernardes JR Jr, Nonogaki S, Seixas MT et al (1999) Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int J Gynaecol Obstet 67:33–38PubMedCrossRef
3.
Zurück zum Zitat Ma XJ, Salunga R, Tuggle JT et al (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100:5974–5979PubMedCrossRef Ma XJ, Salunga R, Tuggle JT et al (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100:5974–5979PubMedCrossRef
4.
Zurück zum Zitat Ciris IM, Bozkurt KK, Baspinar S, Kapucuoglu FN (2011) Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study. Pathol Res Pract 207:182–187PubMedCrossRef Ciris IM, Bozkurt KK, Baspinar S, Kapucuoglu FN (2011) Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study. Pathol Res Pract 207:182–187PubMedCrossRef
5.
Zurück zum Zitat Dedes KJ, Natrajan R, Lambros MB et al (2011) Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer 47:138–150PubMedCrossRef Dedes KJ, Natrajan R, Lambros MB et al (2011) Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer 47:138–150PubMedCrossRef
6.
Zurück zum Zitat Hartmann LC, Sellers TA, Frost MH et al (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353:229–237PubMedCrossRef Hartmann LC, Sellers TA, Frost MH et al (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353:229–237PubMedCrossRef
7.
Zurück zum Zitat Degnim AC, Visscher DW, Berman HK et al (2007) Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 25:2671–2677PubMedCrossRef Degnim AC, Visscher DW, Berman HK et al (2007) Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 25:2671–2677PubMedCrossRef
8.
Zurück zum Zitat McKian KP, Reynolds CA, Visscher DW et al (2009) Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol 27:5893–5898PubMedCrossRef McKian KP, Reynolds CA, Visscher DW et al (2009) Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol 27:5893–5898PubMedCrossRef
9.
Zurück zum Zitat Visscher DW, Pankratz VS, Santisteban M et al (2008) Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 100:421–427PubMedCrossRef Visscher DW, Pankratz VS, Santisteban M et al (2008) Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 100:421–427PubMedCrossRef
10.
Zurück zum Zitat Santisteban M, Reynolds C, Barr Fritcher EG et al (2010) Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat 121:431–437PubMedCrossRef Santisteban M, Reynolds C, Barr Fritcher EG et al (2010) Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat 121:431–437PubMedCrossRef
11.
Zurück zum Zitat Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN (1995) Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 87:1681–1685PubMedCrossRef Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN (1995) Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 87:1681–1685PubMedCrossRef
13.
Zurück zum Zitat Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151PubMedCrossRef Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151PubMedCrossRef
14.
Zurück zum Zitat Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR (1988) A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 128:467–477PubMed Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR (1988) A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 128:467–477PubMed
15.
Zurück zum Zitat London SJ, Connolly JL, Schnitt SJ, Colditz GA (1992) A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941–944PubMedCrossRef London SJ, Connolly JL, Schnitt SJ, Colditz GA (1992) A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941–944PubMedCrossRef
16.
Zurück zum Zitat Milanese TR, Hartmann LC, Sellers TA et al (2006) Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 98:1600–1607PubMedCrossRef Milanese TR, Hartmann LC, Sellers TA et al (2006) Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 98:1600–1607PubMedCrossRef
17.
Zurück zum Zitat Pitanguy I, Torres E, Salgado F, Pires Viana GA (2005) Breast pathology and reduction mammaplasty. Plast Reconstr Surg 115:729–734 discussion 735PubMedCrossRef Pitanguy I, Torres E, Salgado F, Pires Viana GA (2005) Breast pathology and reduction mammaplasty. Plast Reconstr Surg 115:729–734 discussion 735PubMedCrossRef
18.
Zurück zum Zitat Boice JD Jr, Persson I, Brinton LA et al (2000) Breast cancer following breast reduction surgery in Sweden. Plast Reconstr Surg 106:755–762PubMedCrossRef Boice JD Jr, Persson I, Brinton LA et al (2000) Breast cancer following breast reduction surgery in Sweden. Plast Reconstr Surg 106:755–762PubMedCrossRef
19.
Zurück zum Zitat Brown MH, Weinberg M, Chong N, Levine R, Holowaty E (1999) A cohort study of breast cancer risk in breast reduction patients. Plast Reconstr Surg 103:1674–1681PubMedCrossRef Brown MH, Weinberg M, Chong N, Levine R, Holowaty E (1999) A cohort study of breast cancer risk in breast reduction patients. Plast Reconstr Surg 103:1674–1681PubMedCrossRef
20.
Zurück zum Zitat Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRef Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRef
21.
Zurück zum Zitat Rosen PP, Senie R, Schottenfeld D, Ashikari R (1979) Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg 189:377–382PubMedCrossRef Rosen PP, Senie R, Schottenfeld D, Ashikari R (1979) Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg 189:377–382PubMedCrossRef
22.
Zurück zum Zitat Chuba PJ, Hamre MR, Yap J et al (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma-in situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23:5534–5541PubMedCrossRef Chuba PJ, Hamre MR, Yap J et al (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma-in situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23:5534–5541PubMedCrossRef
23.
Zurück zum Zitat Fabian CJ, Kimler BF, Zalles CM et al (2000) Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 92:1217–1227PubMedCrossRef Fabian CJ, Kimler BF, Zalles CM et al (2000) Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 92:1217–1227PubMedCrossRef
24.
Zurück zum Zitat Vierkant RA, Hartmann LC, Pankratz VS et al (2009) Lobular involution: localized phenomenon or field effect? Breast Cancer Res Treat 117:193–196PubMedCrossRef Vierkant RA, Hartmann LC, Pankratz VS et al (2009) Lobular involution: localized phenomenon or field effect? Breast Cancer Res Treat 117:193–196PubMedCrossRef
Metadaten
Titel
Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues
verfasst von
Amy C. Degnim
Daniel W. Visscher
Tanya L. Hoskin
Marlene H. Frost
Robert A. Vierkant
Celine M. Vachon
V. Shane Pankratz
Derek C. Radisky
Lynn C. Hartmann
Publikationsdatum
01.05.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1746-1

Weitere Artikel der Ausgabe 1/2012

Breast Cancer Research and Treatment 1/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.